Technical Analysis for GPCR - Structure Therapeutics Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 38.86 | -3.55% | -1.43 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Flat | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 200 DMA Resistance | Bearish | 0.00% | |
| Fell Below 50 DMA | Bearish | 0.00% | |
| Stochastic Reached Oversold | Weakness | 0.00% | |
| Multiple of Ten Bearish | Other | 0.00% | |
| BB Squeeze Ended | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 20 DMA Resistance | Bearish | -3.55% | |
| 200 DMA Resistance | Bearish | -3.55% | |
| Bollinger Band Squeeze | Range Contraction | -3.55% | |
| Multiple of Ten Bullish | Other | -3.55% |
| Alert | Time |
|---|---|
| 50 DMA Support | about 17 hours ago |
| Fell Below 50 DMA | about 18 hours ago |
| Down 3% | about 18 hours ago |
| Fell Below Previous Day's Low | about 18 hours ago |
| Possible NR7 | about 18 hours ago |
Get a Trading Sidekick!
- Earnings date: 05/09/2024
Structure Therapeutics Inc. Description
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Life Sciences Biology Molecular Biology Obesity Signal Transduction Idiopathic Pulmonary Fibrosis Chronic Disease Diabetes Mellitus Pulmonary Arterial Hypertension Biochemistry Glucagon
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 75.0167 |
| 52 Week Low | 26.61 |
| Average Volume | 640,827 |
| 200-Day Moving Average | 40.57 |
| 50-Day Moving Average | 38.90 |
| 20-Day Moving Average | 41.23 |
| 10-Day Moving Average | 41.66 |
| Average True Range | 2.58 |
| RSI (14) | 44.44 |
| ADX | 20.48 |
| +DI | 16.29 |
| -DI | 15.77 |
| Chandelier Exit (Long, 3 ATRs) | 37.63 |
| Chandelier Exit (Short, 3 ATRs) | 41.97 |
| Upper Bollinger Bands | 44.70 |
| Lower Bollinger Band | 37.77 |
| Percent B (%b) | 0.16 |
| BandWidth | 16.79 |
| MACD Line | 0.41 |
| MACD Signal Line | 0.83 |
| MACD Histogram | -0.4226 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 42.25 | ||||
| Resistance 3 (R3) | 42.53 | 41.69 | 41.69 | ||
| Resistance 2 (R2) | 41.69 | 40.82 | 41.55 | 41.50 | |
| Resistance 1 (R1) | 40.27 | 40.29 | 39.85 | 39.99 | 41.31 |
| Pivot Point | 39.43 | 39.43 | 39.22 | 39.29 | 39.43 |
| Support 1 (S1) | 38.01 | 38.56 | 37.59 | 37.73 | 36.41 |
| Support 2 (S2) | 37.17 | 38.03 | 37.03 | 36.22 | |
| Support 3 (S3) | 35.75 | 37.17 | 36.04 | ||
| Support 4 (S4) | 35.47 |
